88results about How to "Alleviate hypersensitivity" patented technology

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.

An oral care composition includes an effective amount of a basic amino acid in free or salt form; and an effective amount of calcium silicate particles. The calcium silicate particles have an average diameter of less than about 5 microns, such that they can occlude dentinal tubules of the teeth. An oral care method includes applying the composition to an oral cavity of a subject to reduce or inhibit hypersensitivity of the teeth and to achieve other benefits.

This invention provides methods of preserving, improving, or restoring cognitive function in mammal having one or more mutations in the FMR1 gene (e.g. at risk for or having fragile x syndrome), where the methods involve the brain derived neurotrophic factor (BDNF) level or activity in the brain of said mammal. In certain embodiments the methods involve administering one or more AMPA potentiators (e.g., ampakines) to the mammal in an amount sufficient to increase BDNF levels in the brain of the mammal.

A feedback device for measuring balance related information, and for producing a stimulation of the skin that encodes that information in a way that is useful to the wearer of the device. At least one sensor detects balance information and transmits at least one balance information signal to a signal processing subsystem. The signal processing subsystem converts the received balance information signal into at least one stimulation control signal. The signal processing subsystem then transmits the stimulation control signal to at least one stimulator, which provides stimulation to a wearer of the device reflecting the stimulation control signal received from the signal processing subsystem.

Pharmaceutical application of a chemodenervating agent, particularly botulinum toxin, reduces inflammatory response and serves as an anti-inflammatory agent without systemic side effects and with long duration action, on the order of 12-24 weeks. In one embodiment, the effective dosage for allergy provoked inflammation reduction is an order of magnitude less than dosages associated with treatment of regional movement diseases, since the agent works to reduce inflammation by reducing histamine and other preformed mediator releases associated with mast cell degranulation.

This invention relates to compositions comprising a basic amino acid free or salt form and a soluble carbonate or bicarbonate salt.

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

A dental composition which, e.g., eliminates or substantially reduces the discomfort and pain associated with dentinal hypersensitivity and exhibits enhanced anticaries and remineralization benefits, which composition contains a first component containing a calcium source, a second component containing an anion source and at least one of the components containing a basic amino acid in free or salt form, and the first and second components being maintained separate from each other until dispensed and combined for application to teeth.

An oral care composition includes an effective amount of calcium silicate particles. The calcium silicate particles have an average diameter of less than about 5 microns, such that they can occlude dentinal tubules of the teeth. An oral care method includes applying the composition to an oral cavity of a subject to reduce or inhibit hypersensitivity of the teeth and to achieve other benefits.

This invention relates to a dual phase mouthwash comprising a hydrophilic phase, a hydrophobic phase, and a hydrotrope, wherein the hydrophilic phase comprises an effective amount of a preservative selected from methylisothiazolinone, sodium benzoate, potassium sorbate, and combinations thereof, as well as to methods of using and of making such compositions.

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and / or -8 mediated antiport of sodium and / or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and / or salt present in the GI tract.

A method for suppressing the growth of mycobacteria associated with hypersensitivity pneumonitis, in particular Mycobacterium immunogenum, in metalworking fluids is described. The method uses antimicrobial or biocidal compositions which include a metal complex comprising disodium monocopper (II) citrate and an isothiazolone mixture preferably comprising 5-chloro-2-methyl-4-isothiazolin-3-one 2-methyl-4-isothiazolin-3-one. Also described are methods for detecting and identifying the mycobacteria.

The present invention relates to method of preparing dust mite allergen vaccine with nanometer particle as carrier. Dust mite is one of the main allergen causing allergic diseases. The present invention applies biodegradable nanometer PLGA particle as the allergen carrier to coat recombinant dust mite allergen Der p2 / Der f2 in preparing nanometer level dust mite allergen vaccine. Specifically, by means of gene engineering technology, recombinant Der p2 / Der f2 protein is prepared through cloning and expression in colibacillus and PLGA coated nanometer particle is prepared through re-emulsifying and solvent volatizing process. The form, average size, coating rate, medicine carrying amount and extracorporeal accumulation and release curve of the nanometer particle are obtained, and test shows that Der p2 / Der f2-PLGA nanometer particle has certain curative effect on allergic asthma.

The invention provides an alginate dentifrice composition, belonging to the field of personal care products. The alginate dentifrice composition comprises alginate, a zinc ion source, a fluorine-releasing anti-caries agent provided by a nano-scale fluorine-doped zirconia powder, and a desensitizing material provided by a bioactive glass microsphere loading a catechinic acid substance. A method forpreparing the alginate dentifrice composition includes combining the liquid material and the powder material in the raw materials to prepare a mixture, and then combining a surfactant into the mixture, and mixing in a vacuum environment to obtain the dentifrice composition. The astringency of the dentifrice composition is neutralized, and the dentifrice composition can reduce hypersensitivity ofdentin, induce enamel regeneration and enhance porcelain gloss of the tooth surface, relieve oral mucosa, periodontal tissue and pulp damage, and promote formation of prothrombin to reduce bleeding time of gums. The preparation method can promote the phenomenon of agglomeration of anti-caries agent particles and generate tetragonal phase crystals, reduce system energy consumption, increase glass particle loading capacity and hydroxyapatite mineralization production, and improve resource utilization rate and effective yield.

The invention relates to astragalus polyose calcium phosphate nano taxol complex injection and a preparation method and the application thereof. 100 mL of injection comprises the following components: 0.01 to 1 g of astragalus polyose calcium phosphate nano to particles, 1.0 to 50 mg of taxol, 0 to 5.0 g of osmotic pressure regulator and appropriate amount of water. The pH value of the injection is 6.0 to 7.5. The preparation method comprises the following steps: blending the taxol with absolute ethyl alcohol to form taxol-absolute ethyl alcohol solution; blending the astragalus polyose with ultrapure water to form astragalus polyose solution; performing stirring and ultrasonic processing to the solution, rejecting the supernatant fluid after separation, and after depositing, drying and sterilizing, obtaining astragalus polyose calcium phosphate nano taxol complex granules used for injection, then adding the osmotic pressure regulator into the water for injection, and mixing with the astragalus polyose calcium phosphate nano taxol complex granules; after ultrasonic processing, astragalus polyose calcium phosphate nano taxol complex injection is formed. The complex injection can be used for the treatment or auxiliary treatment of tumor.

The present invention is directed to a dental floss comprising a basic amino acid or salt thereof.

Disclosed herein is zinc / amino acid functionalized silica, compositions comprising the same, and oral care methods and uses for such compositions.

Heteroaryl amide analogues are provided, of Formula (I), wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

The invention discloses a digital auditory integrated training system, which comprises a signal source, a power supply, a host and a signal receiving device, the host is electrically connected with the power supply, the signal source is connected with the host by a signal line, and the signal receiving device is communicated and connected with the host. The digital auditory integrated training system of the invention can correct the disorder phenomena of the auditory system on the voice treatment and stimulate the cerebral cortex by listening to a group of music after filtration and modulation, thus achieving the purpose of improving behavior disorders and emotional disorders. The digital auditory integrated training system is safe and reliable, the treatment has no side effects which are serious and existed for a long time, and the digital auditory integrated training system is applicable to: pervasive developmental disorder (PDD), including autism (Infantile Autism) and Asperger syndrome; attention deficit hyperactivity disorder (ADHD); special speech and language developmental disorder (SLD); emotion disorder (ED); learning disorder (LD) and so on.

Disclosed herein are oral care compositions comprising naringin:Zinc complexes having a 2:1 naringin to zinc molar ratio. Methods of making and using the compositions are also provided.

The present invention relates to antigens and methods for the suppression of a hypersensitivity immune response via bystander suppression with an antigen unrelated to the allergen triggering a hypersensitivity immune response such as an allergic response in an individual. Treatment regiments covering the administering the unrelated antigen to the oral cavity (e.g. sublingual mucosa) combined with the administration of the unrelated antigen to either the respiratory tract, gastro-intestinal tract or skin in a simultaneous, contemporaneous, separate or sequential manner is provided.

A macromolecule includes i) a dendrimer comprising a core and at least one generation of building units, the outermost generation of building units having surface amino groups wherein at least two different terminal groups are covalently attached to the surface amino groups of the dendrimer, ii) a first terminal group which is a residue of a pharmaceutically active agent comprising a hydroxyl group, and iii) a second terminal group which is a pharmacokinetic modifying agent. The pharmaceutically active agent is cabazitaxel. The first terminal group is covalently attached to the surface amino group of the dendrimer through a diacid linker, the diacid linker comprising an alkyl chain interrupted by one or more oxygen, sulfur or nitrogen atoms, or a pharmaceutically acceptable salt thereof.

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

This invention relates to dentifrice compositions comprising stannous fluoride and a silica abrasive having a N2 BET surface area of less than 50 m2 / g and an Einlehner hardness of from 4 to 11, as well as to methods of using these compositions.

Disclosed herein are oral care compositions comprising hemp seed oil and caprylyl glycol. In certain embodiments, the oral care composition optionally further comprises one or more ingredients selected from hyaluronic acid and aloe vera. Methods of making and using the compositions are also provided.